Researchers used a screening process that allowed them to test more than 350,000 compounds for their potential to serve as anesthetic agents, in collaboration with the Chemical Genomics Center of the National Center for Advancing Translational Sciences.
Among the 350,000, researchers found 2,600 compounds that had strong interactions with apoferritin, a surrogate anesthetic binding protein target. A subset of the 2,600 were chosen based on structural criteria to be tested for anesthetic activity, first on tadpoles and then on mice. Researchers concluded that two compounds could potentially serve as anesthetics.
“The anesthetics identified by this approach require further development before they can be considered for use in the O.R.,” said Roderic Eckenhoff, MD, lead author of the study and professor of anesthesiology and critical care at Philadelphia-based Perelman School of Medicine at the University of Pennsylvania. “However, the study results show that novel anesthetics do exist, and that we need not restrict ourselves to small modifications of existing drugs.”
More articles on anesthesia:
Somnia Anesthesia to celebrate CRNAs
Dr. Howard Zucker to serve as New York State Department of Health commissioner
Sheridan affiliates with Ambulatory Anesthesia Care
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.